Your session is about to expire
← Back to Search
Cabozantinib + Atezolizumab for Advanced Cancers
Study Summary
This trial is testing the safety and effectiveness of a new cancer drug when used in combination with another cancer drug. The new drug is being tested on people with different types of cancer, including bladder, kidney, prostate, and breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 3 trial • 1028 Patients • NCT01605227Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any major ongoing illnesses, including autoimmune diseases or severe liver problems.I have had platinum-based therapy for my urinary cancer.I have samples of my tumor available for testing.My organs and bone marrow are working well.I have been diagnosed with another cancer within the last 2 years.I am fully active or can carry out light work.I haven't taken high-dose steroids or immunosuppressants in the last 2 weeks.I am 18 years old or older.I am currently taking blood thinners.I have kidney cancer, and it may or may not have been treated before.My side effects from previous treatments are mild or gone.I am not pregnant and can become pregnant.I have not received a live vaccine in the last 30 days.I have not been treated with specific cancer drugs before, except in certain parts of the study.My cancer is confirmed, cannot be removed by surgery, and has spread or come back.My cancer is advanced and cannot be removed by surgery.The doctor can measure your disease using a specific set of guidelines called RECIST 1.1.My brain metastases are treated and stable for at least 4 weeks.
- Group 1: Expansion Cohort 10
- Group 2: Expansion Cohort 14
- Group 3: Expansion Cohort 21 (SAC)
- Group 4: Expansion Cohort 24
- Group 5: Expansion Cohort 3
- Group 6: Expansion Cohort 16
- Group 7: Expansion Cohort 17
- Group 8: Expansion Cohort 18
- Group 9: Expansion Cohort 19 (SAC)
- Group 10: Expansion Cohort 20 (SAC)
- Group 11: Expansion Cohort 22 (SAA)
- Group 12: Expansion Cohort 23
- Group 13: Expansion Cohort 4
- Group 14: Expansion Cohort 2
- Group 15: Expansion Cohort 12
- Group 16: Expansion Cohort 1
- Group 17: Dose Escalation
- Group 18: Expansion Cohort 5
- Group 19: Expansion Cohort 13
- Group 20: Expansion Cohort 6
- Group 21: Expansion Cohort 7
- Group 22: Expansion Cohort 9
- Group 23: Expansion Cohort 11
- Group 24: Expansion Cohort 15
- Group 25: Expansion Cohort 8
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Do we have any other data on cabozantinib?
"Cabozantinib was first studied in 2008 by Can Care Assoc Med Group Inc; Beach Cities Offices. As of now, 134 studies have been completed and there are 457 clinical trials still recruiting patients. The majority of these remaining trials are based in Kettering, Ohio."
How many people are currently enrolled in this experiment?
"As of now, this clinical trial is not looking for any more patients. The first posting was on September 5th, 2017 and the most recent update was on April 8th, 2022. However, there are currently 5372 trials actively recruiting patients with carcinoma, hepatocellular and 457 trials for cabozantinib that have open spots."
How many medical facilities are running this clinical trial?
"With 57 enrolment centres across Kettering, Phoenix and Gilbert -among other locations- there is bound to be a site close to you. This study's proximity policy helps reduce participant burden by lessening travel requirements."
Are individuals still being recruited for this research project?
"From what is conveyed on clinicaltrials.gov, this particular medical trial is not looking for more patients at the current time. The first posting was on September 5th, 2017 and the most recent update was April 8th, 2022. Although this specific study isn't recruiting, there are 5829 other trials that are actively seeking candidates."
What is the first time this particular trial has been conducted?
"Research into cabozantinib began in 2008 with a Phase 1 clinical trial sponsored by Hoffmann-La Roche. After the initial study involving 720 patients, the drug received approval for Phase 2 trials. As of now, there are 457 active trials being conducted in 1957 cities and 75 countries."
What are the primary conditions that cabozantinib is used to treat?
"Cabozantinib can be used to treat small cell lung cancer (SCLC), as well as conditions such as previously treated with anti-VEGF, malignant neoplasms, and high risk patients."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger